Study to investigate the behaviour of paracetamol in the body of patients over 80 years old admitted to an acute geriatric ward

Pharmacokinetic study of paracetamol in patients over 80 years old admitted to an acute geriatric ward

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-004217-24-BE

Enrollment

Registered

2015-10-29

Start date

2015-11-30

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyrexia Pain

Interventions

Trade Name: Dafalgan (paracetamol) Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 80 years or older Admitted to acute geriatric ward of University Hospitals Leuven Oral intake of Dafalgan (paracetamol) tablets, 3 times 1 gram per day for at least 4 intakes before inclusion Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 40

Exclusion criteria

Exclusion criteria: Downgrading of care in terms of palliative situation

Design outcomes

Primary

Measure	Time frame
Main Objective: Pharmacokinetic analysis of paracetamol;Secondary Objective: Not applicable;Primary end point(s): Serum concentration of paracetamol;Timepoint(s) of evaluation of this end point: before intake of a new dose, 30 minutes, 1-2-4-8 hours after	—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Belgium

Contacts

Public ContactKarolien Walgraeve

UZ Leuven

karolien.walgraeve@uzleuven.be+3216341256

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026